Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Substance use Specificities in Women with Psychosis: A Critical Review

Author(s): Francesc Casanovas, Francina Fonseca and Anna Mané*

Volume 21, Issue 9, 2023

Published on: 02 March, 2023

Page: [1953 - 1963] Pages: 11

DOI: 10.2174/1570159X21666221129113942

Price: $65

Abstract

Background: Women with schizophrenia or other psychotic disorders differ from male patients in many respects, including psychopathology, prognosis, disease course, and substance use comorbidities. Most studies performed to date to investigate the association between drug use and psychosis have not evaluated gender differences, although this has started to change in recent years.

Methods: We briefly summarize the available evidence on gender differences in drug use and substance use disorders (SUD) in psychotic patients during the early phases of the psychotic illness and during the course of schizophrenia.

Results: Substance use and SUD are both less prevalent in women, both in the general population and at all phases of the psychotic spectrum. Some studies suggest that SUD may be under diagnosed in female patients, in part due to their more vulnerable profile. Substance use, especially cannabis, may more negatively impact females, especially on the disease course and prognosis. The available data suggest that it may be more difficult to treat SUD in female patients with schizophrenia, which could negatively impact prognosis.

Conclusion: Women with concomitant psychotic illness and SUD comprise a highly vulnerable subgroup. This should be considered when selecting the treatment approach, especially in the early phases of the illness, to ensure better outcomes.

« Previous Next »
Graphical Abstract

[1]
Crockford, D.; Addington, D. Canadian schizophrenia guidelines: Schizophrenia and other psychotic disorders with coexisting substance use disorders. Can. J. Psychiatry, 2017, 62(9), 624-634.
[http://dx.doi.org/10.1177/0706743717720196] [PMID: 28886671]
[2]
Ochoa, S.; Usall, J.; Cobo, J.; Labad, X.; Kulkarni, J. Gender differences in schizophrenia and first-episode psychosis: A comprehensive literature review. Schizophr. Res. Treatment, 2012, 2012, 1-9.
[http://dx.doi.org/10.1155/2012/916198] [PMID: 22966451]
[3]
National Institutes of Health. O.R.W.H. Sex/Gender. Available from: https://orwh.od.nih.gov/research/sex-gender/ Retrieved August 17, 2020.
[4]
Arranz, B.; Safont, G.; Corripio, I.; Ramirez, N.; Dueñas, R.M.; Perez, V.; Alvarez, E.; San, L. Substance use in patients with first-episode psychosis: Is gender relevant? J. Dual Diagn., 2015, 11(3-4), 153-160.
[http://dx.doi.org/10.1080/15504263.2015.1113761] [PMID: 26513726]
[5]
Crosas, J.M.; Cobo, J.; Ahuir, M.; Hernández, C.; García, R.; Pousa, E.; Oliva, J.C.; Monreal, J.A.; Palao, D.J. Substance abuse and gender differences in first episode psychosis: Impact on hospital readmissions. J. Psychiat. Ment. Health, 2018, 11(1), 27-35.
[http://dx.doi.org/10.1016/j.rpsmen.2018.02.003] [PMID: 28648845]
[6]
Lange, E.H.; Nesvåg, R.; Ringen, P.A.; Hartberg, C.B.; Haukvik, U.K.; Andreassen, O.A.; Melle, I.; Agartz, I. One year follow-up of alcohol and illicit substance use in first-episode psychosis: Does gender matter? Compr. Psychiatry, 2014, 55(2), 274-282.
[http://dx.doi.org/10.1016/j.comppsych.2013.08.018] [PMID: 24262129]
[7]
Kozak, K.; H Smith, P. Lowe, D.J.E.; Weinberger, A.H.; Cooper, Z.D.; Rabin, R.A.; George, T.P. A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness. Am. J. Drug Alcohol Abuse, 2021, 47(5), 535-547.
[http://dx.doi.org/10.1080/00952990.2021.1946071] [PMID: 34280058]
[8]
Fonseca, F.; Robles-Martínez, M.; Tirado-Muñoz, J.; Alías-Ferri, M.; Mestre-Pintó, J.I.; Coratu, A.M.; Torrens, M. A gender perspective of addictive disorders. Curr. Addict. Rep., 2021, 8(1), 89-99.
[http://dx.doi.org/10.1007/s40429-021-00357-9] [PMID: 33614395]
[9]
Riecher-Rössler, A.; Butler, S.; Kulkarni, J. Sex and gender differences in schizophrenic psychoses—a critical review. Arch. Women Ment. Health, 2018, 21(6), 627-648.
[http://dx.doi.org/10.1007/s00737-018-0847-9] [PMID: 29766281]
[10]
Sallaup, T.V.; Vaaler, A.E.; Iversen, V.C.; Guzey, I.C. Challenges in detecting and diagnosing substance use in women in the acute psychiatric department: A naturalistic cohort study. BMC Psychiatry, 2016, 16(1), 406.
[http://dx.doi.org/10.1186/s12888-016-1124-y] [PMID: 27855664]
[11]
Plan Nacional Sobre Drogas, Informe 2020. Observatorio Español de la Drogra y las Toxicomanías. 2020. Available from: https://pnsd.sanidad.gob.es/pnsd/
[12]
Brady, K.T.; Randall, C.L. Gender differences in substance use disorders the psychiatric clinics of north america. Addict. Dis., 1999, 22(2), 241-252.
[13]
Erol, A.; Karpyak, V.M. Sex and gender-related differences in alcohol use and its consequences: Contemporary knowledge and future research considerations. Drug Alcohol Depend., 2015, 156, 1-13.
[http://dx.doi.org/10.1016/j.drugalcdep.2015.08.023] [PMID: 26371405]
[14]
Bradley, K.A.; Badrinath, S.; Bush, K.; Boyd-Wickizer, J.; Anawalt, B. Medical risks for women who drink alcohol. J. Gen. Intern. Med., 1998, 13(9), 627-639.
[http://dx.doi.org/10.1046/j.1525-1497.1998.cr187.x] [PMID: 9754520]
[15]
Gilchrist, G.; Blazquez, A.; Torrens, M. Psychiatric, behavioural and social risk factors for HIV infection among female drug users. AIDS Behav., 2011, 15(8), 1834-1843.
[http://dx.doi.org/10.1007/s10461-011-9991-1] [PMID: 21748277]
[16]
Torrens-Melich, M.; Orengo, T.; Rodríguez de Fonseca, F.; Almodóvar, I.; Baquero, A.; Benito, A. Gender perspective in dual diagnosis. Brain Sci., 2021, 11(8), 1101.
[http://dx.doi.org/10.3390/brainsci11081101] [PMID: 34439720]
[17]
Tirado-Muñoz, J.; Gilchrist, G.; Fischer, G.; Taylor, A.; Moskalewicz, J.; Giammarchi, C.; Köchl, B.; Munro, A. Dąbrowska, K.; Shaw, A.; Di Furia, L.; Leeb, I.; Hopf, C.; Torrens, M. Correction to: Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a cross-sectional study. Arch. Women Ment. Health, 2018, 21(3), 271.
[http://dx.doi.org/10.1007/s00737-018-0810-9] [PMID: 29340800]
[18]
Lähteenvuo, M.; Batalla, A.; Luykx, J.J.; Mittendorfer-Rutz, E.; Tanskanen, A.; Tiihonen, J.; Taipale, H. Morbidity and mortality in schizophrenia with comorbid substance use disorders. Acta Psychiatr. Scand., 2021, 144(1), 42-49.
[http://dx.doi.org/10.1111/acps.13291] [PMID: 33650123]
[19]
Ferrer-Farré, T.; Dinamarca, F.; Mestre-Pintó, J.I.; Fonseca, F.; Torrens, M. Dual disorders in the consultation liaison addiction service: Gender perspective and quality of life. J. Clin. Med., 2021, 10(23), 5572.
[http://dx.doi.org/10.3390/jcm10235572] [PMID: 34884274]
[20]
Hodgins, S.; Larm, P.; Westerman, J. Individuals developing schizophrenia are hidden among adolescent substance misusers. Psychol. Med., 2016, 46(14), 3041-3050.
[http://dx.doi.org/10.1017/S0033291716001781] [PMID: 27523641]
[21]
Hjorthøj, C.; Stürup, A.E.; McGrath, J.J.; Nordentoft, M. Years of potential life lost and life expectancy in schizophrenia: A systematic review and meta-analysis. Lancet Psychiatry, 2017, 4(4), 295-301.
[http://dx.doi.org/10.1016/S2215-0366(17)30078-0] [PMID: 28237639]
[22]
Barnes, T.R.E.; Mutsatsa, S.H.; Hutton, S.B.; Watt, H.C.; Joyce, E.M. Comorbid substance use and age at onset of schizophrenia. Br. J. Psychiatry, 2006, 188(3), 237-242.
[http://dx.doi.org/10.1192/bjp.bp.104.007237] [PMID: 16507965]
[23]
McHugh, R.K.; Votaw, V.R.; Sugarman, D.E.; Greenfield, S.F. Sex and gender differences in substance use disorders. Clin. Psychol. Rev., 2018, 66(66), 12-23.
[http://dx.doi.org/10.1016/j.cpr.2017.10.012] [PMID: 29174306]
[24]
Kessler, R.C.; Nelson, C.B.; McGonagle, K.A.; Edlund, M.J.; Frank, R.G.; Leaf, P.J. The epidemiology of co-occuring addictive and mental disorders: Implications for prevention and service utilization. Vol. 1. Am. J. Orthopsychiatry, 1996, 66(1), 17-31.
[25]
Regier, D.A.; Farmer, M.E.; Rae, D.S.; Locke, B.Z.; Keith, S.J.; Judd, L.L.; Goodwin, F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA, 1990, 264(19), 2511-2518.
[PMID: 2232018]
[26]
Weiss, R.D.; Najavits, L.M.; Greenfield, S.F.; Soto, J.A.; Shaw, S.R.; Wyner, D. Validity of substance use self-reports in dually diagnosed outpatients. Am. J. Psychiatry, 1998, 155(1), 127-128.
[http://dx.doi.org/10.1176/ajp.155.1.127] [PMID: 9433351]
[27]
Stone, A.M.; Greenstein, R.A.; Gamble, G.; McLellan, A.T. Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication. Psychiatr. Serv., 1993, 44(2), 176-177.
[http://dx.doi.org/10.1176/ps.44.2.176] [PMID: 8432504]
[28]
Brunette, M.; Drake, R.E. Gender differences in homeless persons with schizophrenia and substance abuse. Community Ment. Health J., 1998, 34(6), 627-642.
[http://dx.doi.org/10.1023/A:1018719203165] [PMID: 9833202]
[29]
Bahorik, A.L.; Newhill, C.E.; Queen, C.C.; Eack, S.M. Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors. Psychol. Med., 2014, 44(1), 61-69.
[http://dx.doi.org/10.1017/S0033291713000548] [PMID: 23551851]
[30]
Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Byerly, M.J.; Glick, I.D.; Canive, J.M.; McGee, M.F.; Simpson, G.M.; Stevens, M.C.; Lieberman, J.A. The national institute of mental health clinical antipsychotic trials of intervention effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophr. Bull., 2003, 29(1), 15-31.
[http://dx.doi.org/10.1093/oxfordjournals.schbul.a006986] [PMID: 12908658]
[31]
Novick, D.; Montgomery, W.; Treuer, T.; Moneta, M.V.; Haro, J.M. Sex differences in the course of schizophrenia across diverse regions of the world. Neuropsychiatr. Dis. Treat., 2016, 12, 2927-2939.
[http://dx.doi.org/10.2147/NDT.S101151] [PMID: 27881918]
[32]
Ayesa-Arriola, R.; de la Foz, V.O.G.; Setién-Suero, E.; Ramírez-Bonilla, M.L.; Suárez-Pinilla, P.; Son, J.M.van Understanding sex differences in long-term outcomes after a first episode of psychosis. npj Schizophr, 2020, 6, 33.
[http://dx.doi.org/10.1038/s41537-020-00120-5]
[33]
González-Pinto, A.; Alberich, S.; Barbeito, S.; Gutierrez, M.; Vega, P.; Ibáñez, B.; Haidar, M.K.; Vieta, E.; Arango, C. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr. Bull., 2011, 37(3), 631-639.
[http://dx.doi.org/10.1093/schbul/sbp126] [PMID: 19915168]
[34]
van der Meer, F.J.; Velthorst, E.; Risk, G.; Group, P. Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study. Psychol. Med., 2015, 45(9), 1977-1988.
[http://dx.doi.org/10.1017/S0033291714003092] [PMID: 25654244]
[35]
Gearon, J.S.; Bellack, A.S. Sex differences in illness presentation, course, and level of functioning in substance-abusing schizophrenia patients. Schizophr. Res., 2000, 43(1), 65-70.
[http://dx.doi.org/10.1016/S0920-9964(99)00175-9] [PMID: 10828416]
[36]
Li, R.; Ma, X.; Wang, G.; Yang, J.; Wang, C. Why sex differences in schizophrenia? J. Transl. Neurosci. (Beijing), 2016, 1(1), 37-42.
[PMID: 29152382]
[37]
Tarrier, N.; Picken, A. Co-morbid PTSD and suicidality in individuals with schizophrenia and substance and alcohol abuse. Soc. Psychiatry Psychiatr. Epidemiol., 2011, 46(11), 1079-1086.
[http://dx.doi.org/10.1007/s00127-010-0277-0] [PMID: 20711764]
[38]
Galderisi, S.; Bucci, P.; Üçok, A.; Peuskens, J. No gender differences in social outcome in patients suffering from schizophrenia. Eur. Psychiatry, 2012, 27(6), 406-408.
[http://dx.doi.org/10.1016/j.eurpsy.2011.01.011] [PMID: 21616645]
[39]
Kendler, K.S.; Lönn, S.L.; Sundquist, J.; Sundquist, K. Smoking and schizophrenia in population cohorts of Swedish women and men: a prospective co-relative control study. Am. J. Psychiatry, 2015, 172(11), 1092-1100.
[http://dx.doi.org/10.1176/appi.ajp.2015.15010126] [PMID: 26046339]
[40]
Reeves, L.E.; Gaudiano, B.A.; Metrik, J.; Guzman Holst, C.; Morena, A.; Sydnor, V.J.; Weinstock, L.M.; Epstein-Lubow, G. Comorbid cannabis and tobacco use disorders in hospitalized patients with psychotic-spectrum disorders. J. Dual Diagn., 2018, 14(3), 171-180.
[http://dx.doi.org/10.1080/15504263.2018.1470359] [PMID: 30265850]
[41]
Khobragade, B.; Sharma, V.; Deshpande, S.N. A study on tobacco use in women with major mental illnesses- schizophrenia, bipolar disorder and recurrent depression. Psychiatry Res., 2020, 290, 113121.
[http://dx.doi.org/10.1016/j.psychres.2020.113121] [PMID: 32505927]
[42]
Li, H.; Li, J.; Yu, X.; Zheng, H.; Sun, X.; Lu, Y.; Zhang, Y.; Li, C.; Bi, X. The incidence rate of cancer in patients with schizophrenia: A meta-analysis of cohort studies. Schizophr. Res., 2018, 195, 519-528.
[http://dx.doi.org/10.1016/j.schres.2017.08.065] [PMID: 28943096]
[43]
Zhuo, C.; Triplett, P.T. Association of schizophrenia with the risk of breast cancer incidence a meta-analysis. JAMA Psychiatry, 2018, 75(4), 363-369.
[http://dx.doi.org/10.1001/jamapsychiatry.2017.4748] [PMID: 29516094]
[44]
González-Rodríguez, A.; Seeman, M.V.; Guàrdia, A.; Natividad, M.; Marín, M.; Labad, J.; Monreal, J.A. Gynecological health concerns in women with schizophrenia and related disorders: A narrative review of recent studies. Women, 2022, 2(1), 1-14.
[http://dx.doi.org/10.3390/women2010001]
[45]
Quigley, H.; MacCabe, J.H. The relationship between nicotine and psychosis. Ther. Adv. Psychopharmacol., 2019, 9, 2045, 12539859969.
[http://dx.doi.org/10.1177/2045125319859969] [PMID: 31308936]
[46]
Calabrese, V.; Mancuso, C.; Calvani, M.; Rizzarelli, E.; Butterfield, D.A.; Giuffrida Stella, A.M. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci., 2007, 8(10), 766-775.
[http://dx.doi.org/10.1038/nrn2214] [PMID: 17882254]
[47]
Perluigi, M.; Di Domenico, F.; Giorgi, A.; Schininà, M.E.; Coccia, R.; Cini, C.; Bellia, F.; Cambria, M.T.; Cornelius, C.; Butterfield, D.A.; Calabrese, V. Redox proteomics in aging rat brain: Involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process. J. Neurosci. Res., 2010, 88(16), 3498-3507.
[http://dx.doi.org/10.1002/jnr.22500] [PMID: 20936692]
[48]
Zhao, F.; Li, B.; Yang, W.; Ge, T.; Cui, R. Brain-immune interaction mechanisms: Implications for cognitive dysfunction in psychiatric disorders. Cell Prolif., 2022, e13295. Online ahead of print
[http://dx.doi.org/10.1111/cpr.13295] [PMID: 35860850]
[49]
Calabrese, V.; Cornelius, C.; Dinkova-Kostova, A.T.; Calabrese, E.J.; Mattson, M.P. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid. Redox Signal., 2010, 13(11), 1763-1811.
[http://dx.doi.org/10.1089/ars.2009.3074] [PMID: 20446769]
[50]
Calabrese, V.; Scuto, M.; Calabrese, E.J. Hormesis, Resilience and Mental Health: Enhancing Public Health and Therapeutic Options Explaining Health Across the Sciences. Healthy Ageing and Longevity; Sholl, J.; Rattan, S.I.S., Eds.; Springer: Cham, Switzerland, 2020, Vol. 12, pp. 497-510.
[51]
Yamashita, A.; Yoshioka, S.; Yajima, Y. Resilience and related factors as predictors of relapse risk in patients with substance use disorder: a cross-sectional study. Subst. Abuse Treat. Prev. Policy, 2021, 16(1), 40.
[http://dx.doi.org/10.1186/s13011-021-00377-8] [PMID: 33388062]
[52]
Portnoy, G.A.; Relyea, M.R.; Decker, S.; Shamaskin-Garroway, A.; Driscoll, M.; Brandt, C.A.; Haskell, S.G. Understanding Gender Differences in Resilience Among Veterans: Trauma History and Social Ecology. J. Trauma. Stress, 2018, 31(6), 845-855.
[http://dx.doi.org/10.1002/jts.22341] [PMID: 30431668]
[53]
Rietschel, L.; Lambert, M.; Karow, A.; Zink, M.; Müller, H.; Heinz, A.; de Millas, W.; Janssen, B.; Gaebel, W.; Schneider, F.; Naber, D.; Juckel, G.; Krüger-Özgürdal, S.; Wobrock, T.; Wagner, M.; Maier, W.; Klosterkötter, J.; Bechdolf, A. Clinical high risk for psychosis: gender differences in symptoms and social functioning. Early Interv. Psychiatry, 2017, 11(4), 306-313.
[http://dx.doi.org/10.1111/eip.12240] [PMID: 25808791]
[54]
Martinotti, G.; Chiappini, S.; Mosca, A.; Miuli, A.; Santovito, M.C.; Pettorruso, M.; Skryabin, V.; Sensi, S.L.; Giannantonio, M.D. Atypical antipsychotic drugs in dual disorders: current evidence and clinical guidelines. Curr. Pharm. Des., 2022, 28.
[PMID: 35747956]
[55]
Skryabin, V.Y.; Vinnikova, M.A.; Ezhkova, E.V.; Titkov, M.S.; Bulatova, R.A. Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study. J. Addict. Dis., 2021, 39(4), 513-525.
[http://dx.doi.org/10.1080/10550887.2021.1905589] [PMID: 33832406]
[56]
Crocker, C.E.; Tibbo, P.G. The interaction of gender and cannabis in early phase psychosis. Schizophr. Res., 2018, 194, 18-25.
[http://dx.doi.org/10.1016/j.schres.2017.04.046] [PMID: 28506705]
[57]
Mazza, M.; Caroppo, E.; De Berardis, D.; Marano, G.; Avallone, C.; Kotzalidis, G.D.; Janiri, D.; Moccia, L.; Simonetti, A.; Conte, E.; Martinotti, G.; Janiri, L.; Sani, G. Psychosis in women: Time for personalized treatment. J. Pers. Med., 2021, 11(12), 1279.
[http://dx.doi.org/10.3390/jpm11121279] [PMID: 34945748]
[58]
Mazzoncini, R.; Donoghue, K.; Hart, J.; Morgan, C.; Doody, G.A.; Dazzan, P.; Jones, P.B.; Morgan, K.; Murray, R.M.; Fearon, P. Illicit substance use and its correlates in first episode psychosis. Acta Psychiatr. Scand., 2010, 121(5), 351-358.
[http://dx.doi.org/10.1111/j.1600-0447.2009.01483.x] [PMID: 19824986]
[59]
Cotton, S.M.; Lambert, M.; Schimmelmann, B.G.; Foley, D.L.; Morley, K.I.; McGorry, P.D.; Conus, P. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr. Res., 2009, 114(1-3), 17-24.
[http://dx.doi.org/10.1016/j.schres.2009.07.002] [PMID: 19635660]
[60]
Faridi, K.; Joober, R.; Malla, A. Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. Schizophr. Res., 2012, 141(1), 78-82.
[http://dx.doi.org/10.1016/j.schres.2012.07.023] [PMID: 22910403]
[61]
Malla, A.; Norman, R.; Bechard-Evans, L.; Schmitz, N.; Manchanda, R.; Cassidy, C. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol. Med., 2008, 38(11), 1585-1593.
[http://dx.doi.org/10.1017/S0033291707002656] [PMID: 18205969]
[62]
Alvarez-Jimenez, M.; Priede, A.; Hetrick, S.E.; Bendall, S.; Killackey, E.; Parker, A.G.; McGorry, P.D.; Gleeson, J.F. Risk factors for relapse following treatment for first episode psychosis: A systematic review and meta-analysis of longitudinal studies. Schizophr. Res., 2012, 139(1-3), 116-128.
[http://dx.doi.org/10.1016/j.schres.2012.05.007] [PMID: 22658527]
[63]
Ricci, V.; Ceci, F.; Di Carlo, F.; Lalli, A.; Ciavoni, L.; Mosca, A.; Sepede, G.; Salone, A.; Quattrone, D.; Fraticelli, S.; Maina, G.; Martinotti, G. Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study. Drug Alcohol Depend., 2021, 229(Pt A), 109118.
[http://dx.doi.org/10.1016/j.drugalcdep.2021.109118] [PMID: 34688166]
[64]
Martinotti, G.; De Risio, L.; Vannini, C.; Schifano, F.; Pettorruso, M.; Di Giannantonio, M. Substance-related exogenous psychosis: a postmodern syndrome. CNS Spectr., 2021, 26(1), 84-91.
[http://dx.doi.org/10.1017/S1092852920001479] [PMID: 32580808]
[65]
Segarra, R.; Ojeda, N.; Peña, J.; García, J.; Rodriguez-Morales, A.; Ruiz, I.; Hidalgo, R.; Burón, J.A.; Eguiluz, J.I.I.; Gutiérrez, M. Longitudinal changes of insight in first episode psychosis and its relation to clinical symptoms, treatment adherence and global functioning: One-year follow-up from the Eiffel study. Eur. Psychiatry, 2012, 27(1), 43-49.
[http://dx.doi.org/10.1016/j.eurpsy.2010.06.003] [PMID: 20813506]
[66]
Abdel-Baki, A.; Ouellet-Plamondon, C.; Salvat, É.; Grar, K.; Potvin, S. Symptomatic and functional outcomes of substance use disorder persistence 2 years after admission to a first-episode psychosis program. Psychiatry Res., 2017, 247(247), 113-119.
[http://dx.doi.org/10.1016/j.psychres.2016.11.007] [PMID: 27888680]
[67]
Jauhar, S.; Johnstone, M.; McKenna, P.J. Schizophrenia. Lancet, 2022, 399(10323), 473-486.
[http://dx.doi.org/10.1016/S0140-6736(21)01730-X] [PMID: 35093231]
[68]
Di Forti, M.; Quattrone, D.; Freeman, T.P.; Tripoli, G.; Gayer-Anderson, C.; Quigley, H.; Rodriguez, V.; Jongsma, H.E.; Ferraro, L.; La Cascia, C.; La Barbera, D.; Tarricone, I.; Berardi, D.; Szöke, A.; Arango, C.; Tortelli, A.; Velthorst, E.; Bernardo, M.; Del-Ben, C.M.; Menezes, P.R.; Selten, J.P.; Jones, P.B.; Kirkbride, J.B.; Rutten, B.P.F.; de Haan, L.; Sham, P.C.; van Os, J.; Lewis, C.M.; Lynskey, M.; Morgan, C.; Murray, R.M.; Amoretti, S.; Arrojo, M.; Baudin, G.; Beards, S.; Bernardo, M.; Bobes, J.; Bonetto, C.; Cabrera, B.; Carracedo, A.; Charpeaud, T.; Costas, J.; Cristofalo, D.; Cuadrado, P.; Díaz-Caneja, C.M.; Ferchiou, A.; Franke, N.; Frijda, F.; García Bernardo, E.; Garcia-Portilla, P.; González, E.; Hubbard, K.; Jamain, S.; Jiménez-López, E.; Leboyer, M.; López Montoya, G.; Lorente-Rovira, E.; Marcelino Loureiro, C.; Marrazzo, G.; Martínez, C.; Matteis, M.; Messchaart, E.; Moltó, M.D.; Nacher, J.; Olmeda, M.S.; Parellada, M.; González Peñas, J.; Pignon, B.; Rapado, M.; Richard, J-R.; Rodríguez Solano, J.J.; Roldán Díaz, L.; Ruggeri, M.; Sáiz, P.A.; Sánchez, E.; Sanjuán, J.; Sartorio, C.; Schürhoff, F.; Seminerio, F.; Shuhama, R.; Sideli, L.; Stilo, S.A.; Termorshuizen, F.; Tosato, S.; Tronche, A-M.; van Dam, D.; van der Ven, E. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry, 2019, 6(5), 427-436.
[http://dx.doi.org/10.1016/S2215-0366(19)30048-3] [PMID: 30902669]
[69]
Marconi, A.; Di Forti, M.; Lewis, C.M.; Murray, R.M.; Vassos, E. Meta-Analysis of the association between the level of cannabis use and risk of psychosis. Schizophr. Bull., 2016, 42(5), 1262-1269.
[http://dx.doi.org/10.1093/schbul/sbw003] [PMID: 26884547]
[70]
Pence, A.Y.; Pries, L.K.; Ferrara, M.; Rutten, B.P.F.; van Os, J.; Guloksuz, S. Gender differences in the association between environment and psychosis. Schizophr. Res., 2022, 243(243), 120-137.
[http://dx.doi.org/10.1016/j.schres.2022.02.039] [PMID: 35287098]
[71]
Donoghue, K.; Doody, G.A.; Murray, R.M.; Jones, P.B.; Morgan, C.; Dazzan, P.; Hart, J.; Mazzoncini, R.; MacCabe, J.H. Cannabis use, gender and age of onset of schizophrenia: Data from the ÆSOP study. Psychiatry Res., 2014, 215(3), 528-532.
[http://dx.doi.org/10.1016/j.psychres.2013.12.038] [PMID: 24461684]
[72]
Rabinowitz, J.; Bromet, E.J.; Lavelle, J.; Carlson, G.; Kovasznay, B.; Schwartz, J.E. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol. Med., 1998, 28(6), 1411-1419.
[http://dx.doi.org/10.1017/S0033291798007399] [PMID: 9854282]
[73]
Myles, H.; Myles, N.; Large, M. Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Aust. N. Z. J. Psychiatry, 2016, 50(3), 208-219.
[http://dx.doi.org/10.1177/0004867415599846] [PMID: 26286531]
[74]
Arranz, S.; Mané, A.; Bergé, D.; Monserrat, C. cabezas, A.; Vilella, E.; Sanchez-Gistau, V. The impact of sex and cannabis on clinical features in first–admitted patients with psychosis. Eur. Neuropsychopharmacol., 2020, 36, 235-243.
[http://dx.doi.org/10.1016/j.euroneuro.2020.03.003] [PMID: 32291209]
[75]
Barbeito, S.; Vega, P.; Ruiz de Azúa, S.; Saenz, M.; Martinez-Cengotitabengoa, M.; González-Ortega, I.; Bermudez, C.; Hernanz, M.; Corres, B.F.; González-Pinto, A. Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study. BMC Psychiatry, 2013, 13(1), 326.
[http://dx.doi.org/10.1186/1471-244X-13-326] [PMID: 24289797]
[76]
Helle, S.; Ringen, P.A.; Melle, I.; Larsen, T.K.; Gjestad, R.; Johnsen, E.; Lagerberg, T.V.; Andreassen, O.A.; Kroken, R.A.; Joa, I.; ten Velden Hegelstad, W.; Løberg, E.M. Cannabis use is associated with 3 years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N = 1119). Schizophr. Res., 2016, 170(1), 217-221.
[http://dx.doi.org/10.1016/j.schres.2015.11.027] [PMID: 26682958]
[77]
Haberstick, B.C.; Young, S.E.; Zeiger, J.S.; Lessem, J.M.; Hewitt, J.K.; Hopfer, C.J. Prevalence and correlates of alcohol and cannabis use disorders in the United States: Results from the national longitudinal study of adolescent health. Drug Alcohol Depend., 2014, 136(1), 158-161.
[http://dx.doi.org/10.1016/j.drugalcdep.2013.11.022] [PMID: 24440049]
[78]
Kelley, M.E.; Wan, C.R.; Broussard, B.; Crisafio, A.; Cristofaro, S.; Johnson, S.; Reed, T.A.; Amar, P.; Kaslow, N.J.; Walker, E.F.; Compton, M.T. Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. Schizophr. Res., 2016, 171(1-3), 62-67.
[http://dx.doi.org/10.1016/j.schres.2016.01.015] [PMID: 26785806]
[79]
Herrmann, E.S.; Weerts, E.M.; Vandrey, R. Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users. Exp. Clin. Psychopharmacol., 2015, 23(6), 415-421.
[http://dx.doi.org/10.1037/pha0000053] [PMID: 26461168]
[80]
Casadio, P.; Fernandes, C.; Murray, R.M.; Di Forti, M. Cannabis use in young people: The risk for schizophrenia. Neurosci. Biobehav. Rev., 2011, 35(8), 1779-1787.
[http://dx.doi.org/10.1016/j.neubiorev.2011.04.007] [PMID: 21530584]
[81]
Kuepper, R.; van Os, J.; Lieb, R.; Wittchen, H.U.; Höfler, M.; Henquet, C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ, 2011, 342(mar01 1), d738.
[http://dx.doi.org/10.1136/bmj.d738] [PMID: 21363868]
[82]
Malone, D.T.; Hill, M.N.; Rubino, T. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br. J. Pharmacol., 2010, 160(3), 511-522.
[http://dx.doi.org/10.1111/j.1476-5381.2010.00721.x] [PMID: 20590561]
[83]
Carr, J.A.R.; Norman, R.G.M.; Manchanda, R. Sociodemographic and clinical characteristics of patients presenting with first-episode psychosis and concurrent substance misuse. Early Interv. Psychiatry, 2009, 3(1), 75-79.
[http://dx.doi.org/10.1111/j.1751-7893.2008.00100.x] [PMID: 21352178]
[84]
Blanchard, J.; Brown, S.A.; Horan, W.P.; Sherwood, A.R. Substance use disorders in schizophrenia Review, integration, and a proposed model. Clin. Psychol. Rev., 2000, 20(2), 207-234.
[http://dx.doi.org/10.1016/S0272-7358(99)00033-1] [PMID: 10721498]
[85]
Bühler, B.; Hambrecht, M.; Löffler, W.; an der Heiden, W.; Häfner, H. Precipitation and determination of the onset and course of schizophrenia by substance abuse — a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res., 2002, 54(3), 243-251.
[http://dx.doi.org/10.1016/S0920-9964(01)00249-3] [PMID: 11950549]
[86]
Di Forti, M.; Sallis, H.; Allegri, F.; Trotta, A.; Ferraro, L.; Stilo, S.A.; Marconi, A.; La Cascia, C.; Reis Marques, T.; Pariante, C.; Dazzan, P.; Mondelli, V.; Paparelli, A.; Kolliakou, A.; Prata, D.; Gaughran, F.; David, A.S.; Morgan, C.; Stahl, D.; Khondoker, M.; MacCabe, J.H.; Murray, R.M. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr. Bull., 2014, 40(6), 1509-1517.
[http://dx.doi.org/10.1093/schbul/sbt181] [PMID: 24345517]
[87]
Van Mastrigt, S.; Addington, J.; Addington, D. Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Psychiatr. Epidemiol., 2004, 39(1), 69-72.
[http://dx.doi.org/10.1007/s00127-004-0713-0] [PMID: 15022049]
[88]
Mauri, M.C.; Volonteri, L.S.; De Gaspari, I.F.; Colasanti, A.; Brambilla, M.A.; Cerruti, L. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin. Pract. Epidemiol. Ment. Health, 2006, 2(1), 4.
[http://dx.doi.org/10.1186/1745-0179-2-4] [PMID: 16556300]
[89]
Veen, N.D.; Selten, J.P.; van der Tweel, I.; Feller, W.G.; Hoek, H.W.; Kahn, R.S. Cannabis use and age at onset of schizophrenia. Am. J. Psychiatry, 2004, 161(3), 501-506.
[http://dx.doi.org/10.1176/appi.ajp.161.3.501] [PMID: 14992976]
[90]
Khantzian, E.J. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv. Rev. Psychiatry, 1997, 4(5), 231-244.
[http://dx.doi.org/10.3109/10673229709030550] [PMID: 9385000]
[91]
Gómez Pérez, L.; Santacana, A.M.; Bergé Baquero, D.; Pérez-Solá, V. Reasons and subjective effects of cannabis use among people with psychotic disorders: a systematic review. Actas Esp. Psiquiatr., 2014, 42(2), 83-90.
[PMID: 24715366]
[92]
Mané, A.; Fernández-Expósito, M.; Bergé, D.; Gómez-Pérez, L.; Sabaté, A.; Toll, A.; Diaz, L.; Diez-Aja, C.; Perez, V. Relationship between cannabis and psychosis: Reasons for use and associated clinical variables. Psychiatry Res., 2015, 229(1-2), 70-74.
[http://dx.doi.org/10.1016/j.psychres.2015.07.070] [PMID: 26235479]
[93]
Setién-Suero, E.; Neergaard, K.; Ramírez-Bonilla, M.; Correa-Ghisays, P.; Fañanás, L.; Crespo-Facorro, B.; Ayesa-Arriola, R. Cannabis use in male and female first episode of non-affective psychosis patients: Long-term clinical, neuropsychological and functional differences. PLoS One, 2017, 12(8), e0183613.
[http://dx.doi.org/10.1371/journal.pone.0183613] [PMID: 28832666]
[94]
Irving, J.; Colling, C.; Shetty, H.; Pritchard, M.; Stewart, R.; Fusar-Poli, P.; McGuire, P.; Patel, R. Gender differences in clinical presentation and illicit substance use during first episode psychosis: a natural language processing, electronic case register study. BMJ Open, 2021, 11(4), e042949.
[http://dx.doi.org/10.1136/bmjopen-2020-042949] [PMID: 33879482]
[95]
Barajas, A.; Ochoa, S.; Obiols, J.E.; Lalucat-Jo, L. Gender differences in individuals at high-risk of psychosis: A comprehensive literature review. ScientificWorldJournal, 2015, 2015, 430735.
[http://dx.doi.org/10.1155/2015/430735] [PMID: 25685840]
[96]
Menghini-Müller, S.; Studerus, E.; Ittig, S.; Heitz, U.; Egloff, L.; Andreou, C.; Valmaggia, L.R.; Kempton, M.J.; van der Gaag, M.; de Haan, L.; Nelson, B.; Barrantes-Vidal, N.; Nordentoft, M.; Ruhrmann, S.; Sachs, G.; Rutten, B.P.; Os, J.; Riecher-Rössler, A.; McGuire, P.; Valmaggia, L.R.; Kempton, M.J.; Calem, M.; Tognin, S.; Modinos, G.; de Haan, L.; van der Gaag, M.; Velthorst, E.; Kraan, T.C.; van Dam, D.S.; Burger, N.; Nelson, B.; McGorry, P.; Amminger, G.P.; Pantelis, C.; Politis, A.; Goodall, J.; Riecher-Rössler, A.; Borgwardt, S.; Rapp, C.; Ittig, S.; Studerus, E.; Smieskova, R.; Bressan, R.; Gadelha, A.; Brietzke, E.; Asevedo, G.; Asevedo, E.; Zugman, A.; Barrantes-Vidal, N.; Domínguez-Martínez, T.; Racioppi, A.; Cristóbal-Narváez, P.; Kwapil, T.R.; Monsonet, M.; Kazes, M.; Daban, C.; Bourgin, J.; Gay, O.; Mam-Lam-Fook, C.; Krebs, M.O.; Nordholm, D.; Randers, L.; Krakauer, K.; Glenthøj, L.; Glenthøj, B.; Nordentoft, M.; Ruhrmann, S.; Gebhard, D.; Arnhold, J.; Klosterkötter, J.; Sachs, G.; Lasser, I.; Winklbaur, B.; Delespaul, P.A.; Rutten, B.P.; van Os, J. Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - results from the EU-GEI study. Eur. Psychiatry, 2019, 59, 52-59.
[http://dx.doi.org/10.1016/j.eurpsy.2019.04.007] [PMID: 31075522]
[97]
Heitz, U.; Studerus, E.; Menghini-Müller, S.; Papmeyer, M.; Egloff, L.; Ittig, S.; Navarra, A.; Andreou, C.; Riecher-Rössler, A. Gender differences in first self-perceived signs and symptoms in patients with an at-risk mental state and first-episode psychosis. Early Interv. Psychiatry, 2019, 13(3), 582-588.
[http://dx.doi.org/10.1111/eip.12528] [PMID: 29235240]
[98]
Wilson, R.P.; Patel, R.; Bhattacharyya, S. Do fewer males present to clinical high-risk services for psychosis relative to first-episode services? Early Interv. Psychiatry, 2017, 11(5), 429-435.
[http://dx.doi.org/10.1111/eip.12311] [PMID: 26818493]
[99]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed; APA: Washington, USA, 2013.
[100]
Beckmann, D.; Lowman, K.L.; Nargiso, J.; McKowen, J.; Watt, L.; Yule, A.M. Substance-induced Psychosis in Youth. Child Adolesc. Psychiatr. Clin. N. Am., 2020, 29(1), 131-143.
[http://dx.doi.org/10.1016/j.chc.2019.08.006] [PMID: 31708042]
[101]
Fraser, S.; Hides, L.; Philips, L.; Proctor, D.; Lubman, D.I. Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people. Schizophr. Res., 2012, 136(1-3), 110-115.
[http://dx.doi.org/10.1016/j.schres.2012.01.022] [PMID: 22321667]
[102]
Murrie, B.; Lappin, J.; Large, M.; Sara, G. Transition of substance-induced, brief, and atypical psychoses to schizophrenia: A systematic review and meta-analysis. Schizophr. Bull., 2020, 46(3), 505-516.
[http://dx.doi.org/10.1093/schbul/sbz102] [PMID: 31618428]
[103]
Arendt, M.; Rosenberg, R.; Foldager, L.; Perto, G.; Munk-Jørgensen, P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br. J. Psychiatry, 2005, 187(6), 510-515.
[http://dx.doi.org/10.1192/bjp.187.6.510] [PMID: 16319402]
[104]
Sara, G.E.; Burgess, P.M.; Malhi, G.S.; Whiteford, H.A.; Hall, W.C. The impact of cannabis and stimulant disorders on diagnostic stability in psychosis. J. Clin. Psychiatry, 2014, 75(4), 349-356.
[http://dx.doi.org/10.4088/JCP.13m08878] [PMID: 24813404]
[105]
Schifano, F.; Napoletano, F.; Chiappini, S.; Guirguis, A.; Corkery, J.M.; Bonaccorso, S.; Ricciardi, A.; Scherbaum, N.; Vento, A. New/emerging psychoactive substances and associated psychopathological consequences. Psychol. Med., 2021, 51(1), 30-42.
[http://dx.doi.org/10.1017/S0033291719001727] [PMID: 31327332]
[106]
Fiorentini, A.; Cantù, F.; Crisanti, C.; Cereda, G.; Oldani, L.; Brambilla, P. Substance-Induced Psychoses: An Updated Literature Review. Front. Psychiatry, 2021, 12, 694863.
[http://dx.doi.org/10.3389/fpsyt.2021.694863] [PMID: 35002789]
[107]
Kendler, K.S.; Ohlsson, H.; Sundquist, J.; Sundquist, K. Prediction of onset of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample. Am. J. Psychiatry, 2019, 176(9), 711-719.
[http://dx.doi.org/10.1176/appi.ajp.2019.18101217] [PMID: 31055966]
[108]
Lamyai, W.; Pono, K.; Indrakamhaeng, D.; Saengsin, A.; Songhong, N.; Khuwuthyakorn, P.; Sribanditmongkol, P.; Junkuy, A.; Srisurapanont, M. Risks of psychosis in methamphetamine users: cross-sectional study in Thailand. BMJ Open, 2019, 9(10), e032711.
[http://dx.doi.org/10.1136/bmjopen-2019-032711] [PMID: 31615802]
[109]
Farnia, V.; Shakeri, J.; Tatari, F.; Juibari, T.A.; Bajoghli, H.; Golshani, S.; Hookari, S.; Holsboer-Trachsler, E.; Brand, S. Demographic and mental history-related data predicted occurrence of psychosis in metamphetamine users. Psychiatry Res., 2016, 240, 431-434.
[http://dx.doi.org/10.1016/j.psychres.2016.04.053] [PMID: 27172885]
[110]
Roncero, C.; Daigre, C.; Grau-López, L.; Barral, C.; Pérez-Pazos, J.; Martínez-Luna, N.; Casas, M. An international perspective and review of cocaine-induced psychosis: a call to action. Subst. Abus., 2014, 35(3), 321-327.
[http://dx.doi.org/10.1080/08897077.2014.933726] [PMID: 24927026]
[111]
Brady, K.T.; Lydiard, R.B.; Malcolm, R.; Ballenger, J.C. Cocaine-induced psychosis. J. Clin. Psychiatry, 1991, 52(12), 509-512.
[PMID: 1752853]
[112]
Mooney, M.; Sofuoglu, M.; Dudish-Poulsen, S.; Hatsukami, D.K. Preliminary observations of paranoia in a human laboratory study of cocaine. Addict. Behav., 2006, 31(7), 1245-1251.
[http://dx.doi.org/10.1016/j.addbeh.2005.08.003] [PMID: 16137832]
[113]
Mahoney, J.J., III; Hawkins, R.Y.; De La Garza, R., II; Kalechstein, A.D.; Newton, T.F. Relationship between gender and psychotic symptoms in cocaine-dependent and methamphetamine-dependent participants. Gend. Med., 2010, 7(5), 414-421.
[http://dx.doi.org/10.1016/j.genm.2010.09.003] [PMID: 21056868]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy